Table 1.
Baseline characteristics
| All patients (n = 239) | Patients without myocardial injury (n = 178) | Patients with myocardial injury (n = 61) | p value | |
|---|---|---|---|---|
| Age (years) (mean ± SD) | 71.5 ± 10.1 | 70.5 ± 10.2 | 74.4 ± 9.4 | 0.007 |
| Age > 75 years n (%) | 97 (40.6%) | 62 (34.8%) | 35 (57.3%) | 0.003 |
| Male n (%) | 134 (56.1%) | 106 (59.6%) | 28 (45.9%) | 0.07 |
| BMI kg/m2 (mean ± SD) | 26.8 ± 4.7 | 26.8 ± 4.6 | 27.1 ± 5.3 | 0.809 |
| Past medical history | ||||
| Hypertension n (%) | 183 (76.6%) | 133 (74.7%) | 50 (82%) | 0.295 |
| Diabetes mellitus n (%) | 138 (57.7%) | 100 (56.2%) | 38 (62.3%) | 0.454 |
| Insulin treatment | 108 (45.2%) | 78 (43.8%) | 30 (49.2%) | 0.551 |
| CAD n (%) | 115 (48.1%) | 81 (45.5%) | 34 (55.7) | 0.184 |
| Myocardial infarction n (%) | 59 (24.7%) | 41 (23.0%) | 18 (29.5%) | 0.308 |
| TIA/stroke n (%) | 44 (18.4%) | 32 (18.0%) | 12 (20%) | 0.848 |
| Chronic heart failure n (%) | 48 (20.1%) | 28 (15.7%) | 20 (32.8%) | 0.006 |
| Dialysis n (%) | 12 (5.0%) | 8 (4.5%) | 4 (6.6%) | 0.508 |
| Prior smoker n (%) | 170 (71.1%) | 126 (70.8%) | 44 (72.1%) | 0.872 |
| Current smoker n (%) | 30 (12.6%) | 25 (14.0%) | 5 (8.2%) | 0.271 |
| Rutherford 4 n (%) | 49 (20.5%) | 40 (22.5%) | 9 (14.8%) | 0.2698 |
| Rutherford 5 n (%) | 150 (62.8%) | 112 (62.9%) | 38 (62.3%) | 1 |
| Rutherford 6 n (%) | 40 (16.7%) | 26 (14.6%) | 14 (23%) | 0.163 |
| Treatment | ||||
| ASA | 234 (97.9%) | 174 (97.8%) | 60 (98.4%) | 1 |
| Clopidogrel | 227 (95.0%) | 171 (96.1%) | 56 (91.8%) | 0.1895 |
| Statin | 208 (87.0%) | 160 (89.9%) | 48 (78.7%) | 0.044 |
| B-blocker | 141 (59.0%) | 95 (53.4%) | 46 (75.4%) | 0.003 |
| ACE inhibitor | 144 (60.3%) | 104 (58.4%) | 40 (65.6%) | 0.365 |
| Heparin | 165 (69.0%) | 118 (66.3%) | 47 (77%) | 0.149 |
| Oral diabetes drugs | 55 (23.0%) | 42 (23.6%) | 13 (21.3%) | 0.86 |
| Laboratory parameters | ||||
| Hb g/dL | 12.4 (10.9–13.5) | 12.6 (11.3–13.6) | 11.4 (10.6–12.4) | 0.001 |
| WBC count × 103 cells/μ/L | 8.2 (6.9–10.8) | 8.0 (6.74–10.8) | 8.7 (7.5–10.9) | 0.04 |
| Platelet count × 103 cells/μ/L | 233.5 (190–311) | 230 (190–307) | 255 (194–319) | 0.622 |
| CRP mg/L | 7.4 (2.1–41.2) | 6.1 (1.8–28.8) | 15.5 (2.8–61.2) | 0.019 |
| CRP > 5 mg/L n (%) | 144 (60.3%) | 100 (56.2%) | 44 (72.1%) | 0.034 |
| Creatinine μmol/L | 83 (67–102) | 81 (65.5–99) | 87 (68.8–110) | 0.22 |
| eGFR | 74 (56–96) | 78 (57.3–98.8) | 65.5 (50.3–87.8) | 0.031 |
| Preoperative hsTnT ng/L | 18 (12–29) | 17 (11–27) | 22 (14–35.5) | 0.017 |
| NT-proBNP pg/ml median (Q1–Q3) | 558 (195–1565) | 459 (159–1365) | 1061 (471–2490) | < 0.001 |
Continuous variables expressed as medians with 25–75 quartile range unless otherwise specified
ACE angiotensin converting enzyme, ASA acetylsalicylic acid, BMI body mass index, CAD coronary artery disease, CRP C-reactive protein, GFR glomerular filtration rate, HgB hemoglobin, hsTnT high-sensitive troponin T, NT-proBNP N-terminal brain natriuretic peptide, SD standard deviation, TIA transient ischemic attack, WBC white blood cells